ADMA Biologics Net Worth
ADMA Biologics Net Worth Breakdown | ADMA |
ADMA Biologics Net Worth Analysis
ADMA Biologics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ADMA Biologics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ADMA Biologics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ADMA Biologics' net worth analysis. One common approach is to calculate ADMA Biologics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ADMA Biologics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ADMA Biologics' net worth. This approach calculates the present value of ADMA Biologics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ADMA Biologics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ADMA Biologics' net worth. This involves comparing ADMA Biologics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ADMA Biologics' net worth relative to its peers.
Enterprise Value |
|
To determine if ADMA Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ADMA Biologics' net worth research are outlined below:
| ADMA Biologics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 258.21 M. Net Loss for the year was (28.24 M) with profit before overhead, payroll, taxes, and interest of 35.27 M. | |
| ADMA Biologics has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from accesswire.com: ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm |
ADMA Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ADMA Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ADMA Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know ADMA Biologics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ADMA Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ADMA Biologics backward and forwards among themselves. ADMA Biologics' institutional investor refers to the entity that pools money to purchase ADMA Biologics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-06-30 | 4 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 4 M | Magnetar Financial Llc | 2024-06-30 | 3.7 M | Renaissance Technologies Corp | 2024-09-30 | 3.7 M | Assenagon Asset Management Sa | 2024-09-30 | 3.5 M | Deutsche Bank Ag | 2024-06-30 | 3 M | Driehaus Capital Management Llc | 2024-06-30 | 3 M | Northern Trust Corp | 2024-09-30 | 2.4 M | Charles Schwab Investment Management Inc | 2024-09-30 | 2.4 M | Blackrock Inc | 2024-06-30 | 18.6 M | Vanguard Group Inc | 2024-09-30 | 18.1 M |
Follow ADMA Biologics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.05 B.Market Cap |
|
Project ADMA Biologics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.09) | (0.09) | |
| Return On Capital Employed | 0.08 | 0.07 | |
| Return On Assets | (0.09) | (0.09) | |
| Return On Equity | (0.21) | (0.20) |
When accessing ADMA Biologics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ADMA Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ADMA Biologics' profitability and make more informed investment decisions.
Please note, the presentation of ADMA Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ADMA Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ADMA Biologics' management manipulating its earnings.
Evaluate ADMA Biologics' management efficiency
ADMA Biologics has return on total asset (ROA) of 0.1989 % which means that it generated a profit of $0.1989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3555 %, meaning that it created $0.3555 on every $100 dollars invested by stockholders. ADMA Biologics' management efficiency ratios could be used to measure how well ADMA Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, ADMA Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 269.9 M, whereas Other Assets are forecasted to decline to 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.60 | 0.90 | |
| Tangible Book Value Per Share | 0.59 | 0.85 | |
| Enterprise Value Over EBITDA | 215.32 | 226.09 | |
| Price Book Value Ratio | 7.49 | 7.86 | |
| Enterprise Value Multiple | 215.32 | 226.09 | |
| Price Fair Value | 7.49 | 7.86 | |
| Enterprise Value | 1.1 B | 1.2 B |
ADMA Biologics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 12.8038 | Revenue 382.8 M | Quarterly Revenue Growth 0.781 | Revenue Per Share 1.661 | Return On Equity 0.3555 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADMA Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADMA Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADMA Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADMA Biologics Corporate Filings
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
ADMA Biologics Earnings per Share Projection vs Actual
ADMA Biologics Corporate Management
| CPA CPA | CFO VP | Profile | |
| Michael Goldstein | Sr Counsel | Profile | |
| Neal Fitzpatrick | Vice Sales | Profile | |
| Kaitlin Kestenberg | Project Compliance | Profile | |
| Cyndi Tolman | VP Services | Profile | |
| Dr DPS | CoFounder Chairman | Profile |
Already Invested in ADMA Biologics?
The danger of trading ADMA Biologics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADMA Biologics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADMA Biologics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADMA Biologics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.28 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.